Zoeken

Uw resultaten

Resultaat 10 van 18 resultaten

Antimicrobial resistance (the ability of a microorganism to survive in the presence of a medicine designed to inhibit or kill it) is threatening the capacity to prevent and cure infectious diseases. In the European Union, it causes an estimated 35 000 deaths per year, and places an annual financial burden of €1.1 billion on healthcare systems. In 2019, the World Health Organization declared antimicrobial resistance (AMR) to be one of the top 10 global public health threats facing humanity. On 26 ...

On 26 Avril 2023, the European Commission put forward a 'pharmaceutical package' to revise the EU's pharmaceutical legislation and make medicines more available, accessible and affordable, while supporting the competitiveness and attractiveness of the EU pharmaceutical industry, with higher environmental standards. The package includes proposals for a new directive and a new regulation, which would replace the existing pharmaceutical legislation, including the legislation on medicines for children ...

Antimicrobial resistance (AMR) is a global, multidimensional phenomenon occurring in humans, animals, and environmental ecosystems. It is the ability of microbes, e.g. bacteria, viruses, fungi and protozoa, to survive in the presence of medicines designed to kill or inactivate them (antimicrobials: antibiotics, antivirals, antifungals and antiprotozoals). At patient level, AMR hampers the effective treatment of microbial infections, leading to prolonged, severe disease and, in some cases, death. ...

These proceedings summarise the presentations and discussions before the European Parliament’s Health Working Group as part of the workshop on ‘New incentives to improve the accessibility and availability of antimicrobial medicinal products’, held on 26 October 2022. The five presentations touched, inter alia, upon the burden of AMR, the current research on development of antimicrobials, and incentive models. These workshop proceedings were provided by the Policy Department for Economic, Scientific ...

Antimicrobial-resistant infections are predicted to become the second biggest cause of death worldwide by 2050. Despite increasing investment in the development of new antimicrobials, awareness campaigns on antimicrobial misuse and abuse, and monitoring of antimicrobial use and resistance in animals, humans and the environment, antimicrobial resistance continues to grow and the last three decades have not seen even one novel antimicrobial class reach the market. Could the answer lie in a 'Trojan ...

Scientific evidence indicates that beneficial microorganisms (that live in nearly ubiquitous communities called microbiota) are an essential component of human health, and could be a new frontier for personalised medicine to fight non-communicable diseases and improve human health. For their potential benefits to reach society, the EU should consider standardisation, protocols, and a regulatory framework to support research and innovation.

In 2014, the Commission presented a proposal for a regulation on medicated feed with the aim to update and harmonise rules that dated from 1990 and were laid out in a directive. Patchy national implementation was causing difficulties for producers, animal holders and the single market. Due to the strong correlation between the proposal on medicated feed and the draft regulation on veterinary medicinal products, legislative work on both acts was being coordinated to assure consistency between their ...

Recent research suggests that the future combat against antimicrobial resistance (AMR) may involve probiotic-based approaches. Their use in our microbial ecosystems, including humans, animals and the healthcare environment, may provide a novel approach which deserves exploration.

Serious threats to health – such as those due to infectious disease outbreaks or environmental factors – do not respect borders. They do, however, require cross-border cooperation and a coordinated response. Decision No 1082/2013/EU is the framework for European Union action on health emergencies. It provides for information exchange, risk assessment and joint procurement, among other mechanisms. The EU-level response is coordinated by the Health Security Committee. The European Centre for Disease ...

The commissioner-designate, Stella Kyriakides, appeared before the Environment, Public Health and Food Safety Committee of the European Parliament on 01 October 2019 to answer MEPs’ questions. During the hearing, she made a number of oral commitments which are highlighted in this document. These commitments refer to her portfolio, as described in the mission letter sent to her by Ursula von der Leyen, President-elect of the European Commission, including "protecting and promoting public health" and ...